Because the combination with the downregulation of tumour suppressors and genes involved in cell proliferation is a candidate for synthetic lethality, cytoplasmic PRMT5/MEP50 may be a therapeutic target in NDRG2low cancers. This evidence concerns the gene WDR77 and neoplasm.